Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts

Affiliations

¹ Division of Nephrology, University of British Columbia, British Columbia, Vancouver, Canada.
² BC Renal, Vancouver, Canada.
³ Fondazione Ricerca Molinette, Regina Margherita Hospital, Turin, Italy.
⁴ Cardiovascular Sciences, University of Leicester, Leicester, UK.
⁵ Stanford University Medical Center, Stanford, California, USA.
⁶ Department Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, the Netherlands.
⁷ University of Alabama at Birmingham, Birmingham, Alabama, USA.
⁸ Mount Elizabeth Novena Hospital, Singapore.
⁹ George Institute for Global Health, New Delhi, India.
¹⁰ School of Public Health, Imperial College, London, UK.
¹¹ Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India.
¹² Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
¹³ Juntendo University, Faculty of Medicine, Tokyo, Japan.
¹⁴ Hospital Británico de Buenos Aires, Buenos Aires, Argentina.
¹⁵ Division of Nephrology, University of Toronto, Toronto, Ontario, Canada.

Sean J Barbour et al. Kidney Int Rep. 2025.

. 2025 Jan 20;10(4):1283-1287.

doi: 10.1016/j.ekir.2025.01.025. eCollection 2025 Apr.

¹ Division of Nephrology, University of British Columbia, British Columbia, Vancouver, Canada.
² BC Renal, Vancouver, Canada.
³ Fondazione Ricerca Molinette, Regina Margherita Hospital, Turin, Italy.
⁴ Cardiovascular Sciences, University of Leicester, Leicester, UK.
⁵ Stanford University Medical Center, Stanford, California, USA.
⁶ Department Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, the Netherlands.
⁷ University of Alabama at Birmingham, Birmingham, Alabama, USA.
⁸ Mount Elizabeth Novena Hospital, Singapore.
⁹ George Institute for Global Health, New Delhi, India.
¹⁰ School of Public Health, Imperial College, London, UK.
¹¹ Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India.
¹² Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
¹³ Juntendo University, Faculty of Medicine, Tokyo, Japan.
¹⁴ Hospital Británico de Buenos Aires, Buenos Aires, Argentina.
¹⁵ Division of Nephrology, University of Toronto, Toronto, Ontario, Canada.

Erratum in

Erratum to "Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts" [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1283-1287].
Barbour SJ, Coppo R, Barratt J, Er L, Lafayette R, Heerspink HJL, Rizk DV, Liew A, Jha V, Zhang H, Suzuki Y, Trimarchi H, Cattran DC; International IgA Nephropathy Network Research Group. Barbour SJ, et al. Kidney Int Rep. 2025 May 16;10(7):2506. doi: 10.1016/j.ekir.2025.05.026. eCollection 2025 Jul. Kidney Int Rep. 2025. PMID: 40677352 Free PMC article.

No abstract available

1. Inker L.A., Mondal H., Greene T., et al. Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis. Am J Kidney Dis. 2016;68:392–401. doi: 10.1053/j.ajkd.2016.02.042. - DOI - PubMed
1. Inker L.A., Heerspink H.J.L., Tighiouart H., et al. Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy: an individual participant meta-analysis. Am J Kidney Dis. 2021;78:340–349.e1. doi: 10.1053/j.ajkd.2021.03.007. - DOI - PMC - PubMed
1. Barbour S.J., Coppo R., Zhang H., et al. Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy. Kidney Int. 2022;102:160–172. doi: 10.1016/j.kint.2022.02.042. - DOI - PubMed
1. Barbour S.J., Coppo R., Er L., et al. Updating the International IgA Nephropathy Prediction Tool for use in children. Kidney Int. 2021;99:1439–1450. doi: 10.1016/j.kint.2020.10.033. - DOI - PubMed
1. Barbour S.J., Coppo R., Zhang H., et al. Evaluating a new international risk-prediction Tool in IgA nephropathy. JAMA Intern Med. 2019;179:942–952. doi: 10.1001/jamainternmed.2019.0600. - DOI - PMC - PubMed